Physician profile

Chan Eui Hong

Emergency Medicine · Weirton, WV

NPI 1548827645

$310.88

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$260.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Inari Medical, INC. $195.81 2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Astrazeneca Pharmaceuticals LP $32.52 2024 Andexxa
Csl Behring $32.05 2024 Kcentra
Mylan Specialty L.P. $16.30 2022
Astellas Pharma US INC $11.90 2021
Nestle Healthcare Nutrition INC. $11.31 2021
Merck Sharp & Dohme LLC $10.99 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chan Eui Hong

$310.88

in general payments reported 2019-2025

Years
2019-2024
Top company
Inari Medical, INC.

https://glasscript.com/doctor/6496919/chan-eui-hong

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.